SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share),…

MiNK Therapeutics · PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $8.8M from $9.5M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.

  • Q2 2026 net loss $3.1M ($0.62/share) vs $4.2M ($1.06/share) in Q2 2025
  • Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
  • First patients in randomized Phase 2 trial C-1300-02 alive at Day 28 with improved oxygenation and reduced inflammatory markers
  • Launched paid named-patient access program in Brazil for agenT-797, potentially generating program revenue

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access